SCHEMBL25858259

SCHEMBL25858259

Cc1cc(Nc2ccncc2)nc(NC(=O)Nc2ccc(Cl)c(C)c2)n1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BLM P54132 2/20 0.52
APOBEC3A P31941 1/20 0.50
APOBEC3G Q9HC16 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
KMT2A Q03164 7/20 0.46
MEN1 O00255 6/20 0.45
LMNA P02545 1/20 0.45
MAPT P10636 1/20 0.45
RAB9A P51151 2/20 0.45
NPC1 O15118 2/20 0.45
SLC2A1 P11166 2/20 0.44
PDPK1 O15530 1/20 0.43
KDM4E B2RXH2 1/20 0.43
EGFR P00533 1/20 0.43
CCNC P24863 1/20 0.43
CDK8 P49336 1/20 0.43
POLB P06746 1/20 0.42
SMARCA2 P51531 1/20 0.42
SMARCA4 P51532 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18038012 0.92 NPC1 (0.54) BLMAPOBEC3AAPOBEC3GL3MBTL1KMT2A
SCHEMBL18017349 0.87 APOBEC3A (0.44) BLMAPOBEC3AAPOBEC3GL3MBTL1KMT2A
SCHEMBL25858253 0.81 BLM (0.50) BLMKMT2AMEN1LMNAMAPT
SCHEMBL24009862 0.80 KMT2A (0.58) BLMAPOBEC3AAPOBEC3GL3MBTL1KMT2A
SCHEMBL25858218 0.79 SLC2A1 (0.60) BLMKMT2AMAPTRAB9ANPC1
SCHEMBL25858213 0.78 KMT2A (0.45) BLMAPOBEC3AAPOBEC3GL3MBTL1KMT2A
SCHEMBL25734784 0.76 KMT2A (0.47) BLMAPOBEC3AAPOBEC3GL3MBTL1KMT2A
SCHEMBL25858229 0.76 DNM2 (0.45) BLMKMT2AMEN1MAPTRAB9A
SCHEMBL18017333 0.74 MEN1 (0.44) APOBEC3AAPOBEC3GL3MBTL1KMT2AMEN1
SCHEMBL16319530 0.74 APOBEC3A (0.44) APOBEC3AAPOBEC3GL3MBTL1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230321094-A1 COMBINATION THERAPIES WITH OLIG2 INHIBITORS Curtana Pharmaceuticals, Inc. 2023-10-12 US disclosed
US-20230271926-A1 INHIBITION OF OLIG2 ACTIVITY Curtana Pharmaceuticals, Inc. 2023-08-31 US disclosed
US-11691951-B2 Inhibition of Olig2 activity Curtana Pharmaceuticals, Inc. (US) 2023-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691951-B2 Inhibition of Olig2 activity GLI2, ING2, GMFG BLM 4472/4885APOBEC3A 4454/4885APOBEC3G 3978/4885
US-20230321094-A1 COMBINATION THERAPIES WITH OLIG2 INHIBITORS PAX2, GLI2, RUNX1 BLM 3317/4885APOBEC3A 4007/4885APOBEC3G 3558/4885
US-20230271926-A1 INHIBITION OF OLIG2 ACTIVITY GLI2, ING2, GMFG BLM 4472/4885APOBEC3A 4454/4885APOBEC3G 3978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.